Role of Skin Cleansing and Prophylactic Antibiotic in Preventing Infectious Morbidity After Cesarean Section Delivery

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03007706

Enrollment

200

Registered

2017-01-02

Start date

2017-01-31

Completion date

2017-10-31

Last updated

2017-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Infectious Morbidity in Cesarean Section Delivery

Brief summary

This study aims to determine the effectiveness of skin cleansing and prophylactic antibiotics given to women undergoing a cesarean section for reducing the incidence of postpartum infectious morbidity and to assess potential maternal adverse effects and any impact on the infant.

Interventions

PROCEDUREWomen undergo cesarean section delivery

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

1. Women undergoing cesarean delivery, both elective and non-elective. 2. Rupture of membranes and labor contractions will be allowed.

Exclusion criteria

1. Unknown outcome from the patient. 2. Refusing to participate in the study from the admission conse 3. Allergy to antibiotics. 4. Any visible infection.

Design outcomes

Primary

Measure	Time frame
role of skin cleansing and prophylactic antibiotics given to women undergoing a cesarean section for reducing the incidence of postpartum infectious morbidity	2 weeks following cesarean section

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026